1996•PubMedRequires access

The position of recently developed broad-spectrum cephem antibiotics in bacterial septicemia.

Shah Pm

Open publisher page 0 citations

Abstract

In-vitro studies with cefpirome or cefepime prove that both agents are highly active against Gram-negative bacilli and Gram-positive cocci. They possess a broader spectrum of activity than ceftazidime. In clinical trials cefpirome at doses ranging from 1 g to 2 g b.i.d. was compared to ceftazidime at a dose ranging from 1 g to 2 g b.i.d. or 2 g t.i.d. Cefepime at a dose of 2 g b.i.d. was compared to ceftazidime at a dose of 2 g t.i.d. Both cefpirome and cefepime were found to be as effective as ceftazidime in patients with septicemia. These new compounds are a valuable addition to the range of drugs available for empiric treatment of serious bacterial infections.

About this research paper

What this paper is about

In-vitro studies with cefpirome or cefepime prove that both agents are highly active against Gram-negative bacilli and Gram-positive cocci. They possess a broader spectrum of activity than ceftazidime. In clinical trials cefpirome at doses ranging from 1 g to 2 g b.i.d. was compared to ceftazidime at a dose ranging from 1 g to 2 g b.i.d. or 2 g t.i.d. Cefepime at a dose of 2 g b.i.d. was compared to ceftazidime at a dose of 2 g t.i.d. Both cefpirome and cefepime were found to be as effective as ceftazidime in patients with septicemia. These new compounds are a valuable addition to the range of drugs available for empiric treatment of serious bacterial infections.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In-vitro studies with cefpirome or cefepime prove that both agents are highly active against Gram-negative bacilli and Gram-positive cocci. They possess a broader spectrum of activity than ceftazidime. In clinical trials cefpirome at doses ranging from 1 g to 2 g b.i.d. was compared to ceftazidime at a dose ranging from 1 g to 2 g b.i.d. or 2 g t.i.d. Cefepime at a dose of 2 g b.i.d. was compared to ceftazidime at a dose of 2 g t.i.d. Both cefpirome and cefepime were found to be as effective as ceftazidime in patients with septicemia. These new compounds are a valuable addition to the range of drugs available for empiric treatment of serious bacterial infections.

Key concepts: Cefpirome, Cefepime, Ceftazidime, Cephem, Cephalosporin, Bacilli, Antibiotics, Microbiology

Related papers

Back to paper searchBrowse research topicsOriginal source
The position of recently developed broad-spectrum cephem antibiotics in bacterial septicemia. — Research Paper | ScholarLens